Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Yearbook of Neurology and Neurosurgery ◽

10.1016/s0513-5117(09)79049-0 ◽

2009 ◽

Vol 2009 ◽

pp. 99-103

Author(s):

O. Kantarci

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

The Lancet ◽

10.1016/s0140-6736(08)60918-6 ◽

2008 ◽

Vol 371 (9630) ◽

pp. 2085-2092 ◽

Cited By ~ 187

Author(s):

G Comi ◽

A Pulizzi ◽

M Rovaris ◽

O Abramsky ◽

T Arbizu ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

The Lancet Neurology ◽

10.1016/s1474-4422(08)70173-x ◽

2008 ◽

Vol 7 (9) ◽

pp. 796-804 ◽

Cited By ~ 326

Author(s):

Benjamin M Segal ◽

Cris S Constantinescu ◽

Aparna Raychaudhuri ◽

Lilianne Kim ◽

Rosanne Fidelus-Gort ◽

...

Keyword(s):

Multiple Sclerosis ◽

Phase Ii ◽

Double Blind ◽

Subcutaneous Injections ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Dose Ranging ◽

Randomised, double blind, placebo controlled study of interferon beta -1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp.67.4.451 ◽

1999 ◽

Vol 67 (4) ◽

pp. 451-456 ◽

Cited By ~ 18

Author(s):

C. Liu ◽

L. D Blumhardt

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial

The Lancet Neurology ◽

10.1016/s1474-4422(11)70299-x ◽

2012 ◽

Vol 11 (2) ◽

pp. 131-139 ◽

Cited By ~ 54

Author(s):

David H Miller ◽

Thomas Weber ◽

Richard Grove ◽

Claire Wardell ◽

Joseph Horrigan ◽

...

Keyword(s):

Multiple Sclerosis ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Faculty Opinions recommendation of Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1115662.580395 ◽

2008 ◽

Author(s):

Nancy Richert ◽

Francesca Bagnato

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial

Neurology ◽

10.1212/wnl.43.4.662 ◽

1993 ◽

Vol 43 (4) ◽

pp. 662-662 ◽

Cited By ~ 830

Author(s):

D. W. Paty ◽

D.K.B. Li ◽

◽

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

The Lancet Neurology ◽

10.1016/s1474-4422(21)00179-4 ◽

2021 ◽

Vol 20 (9) ◽

pp. 709-720 ◽

Cited By ~ 1

Author(s):

J William L Brown ◽

Nick G Cunniffe ◽

Ferran Prados ◽

Baris Kanber ◽

Joanne L Jones ◽

...

Keyword(s):

Multiple Sclerosis ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Parallel Group ◽

Relapsing Remitting ◽

FP36-WE-03 MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study

Journal of the Neurological Sciences ◽

10.1016/s0022-510x(09)70458-7 ◽

2009 ◽

Vol 285 ◽

pp. S114 ◽

Cited By ~ 1

Author(s):

G. Comi ◽

S. Cook ◽

G. Giovannoni ◽

K. Rammohan ◽

P. Rieckmann ◽

...

Keyword(s):

Multiple Sclerosis ◽

Oral Treatment ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Short Course ◽

Relapsing Remitting ◽

FP36-WE-02 Clinical outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study

Journal of the Neurological Sciences ◽

10.1016/s0022-510x(09)70457-5 ◽

2009 ◽

Vol 285 ◽

pp. S114

Author(s):

G. Giovannoni ◽

G. Comi ◽

S. Cook ◽

K. Rammohan ◽

P. Rieckmann ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Outcomes ◽

Oral Treatment ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Short Course ◽

Relapsing Remitting ◽